Immunocore Holdings plc American Depositary Shares (IMCR)
Stock · NASDAQ · Health Care
$29.43as of 10/16/2026
Price chart
Active signals
IMCR Signal Track Record
How signals performed across all stocks →What IMCR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -0.9% | 49% | October 1, 2026 |
| Bollinger Band Breakdown | 23 | -0.8% | 48% | September 10, 2026 |
| Bollinger Band Breakout | 21 | +1.9% | 52% | August 18, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +7.6% | 64% | September 11, 2026 |
| Any 20-session window (baseline) | -1.2% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMCR
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in P…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 524
- Website
- www.immunocore.com/
Fundamentals
- 1-day range
- $28.73$29.9
- Market cap
- $1.66B
- P/E (trailing)
- —
- P/E (forward)
- -39.08
- EPS (trailing)
- $-0.37
- Dividend yield
- —
- Beta
- 0.82
- Avg. volume
- 425.2K
How Immunocore Holdings plc American Depositary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Immunocore Holdings plc American Depositary Shares Competitors
Chosen by industry and closest market cap.
- IMCRImmunocore Holdings plc American Depositary Shares$29.4▼ 0.27%Market cap $1.66BP/E —$27.5$40.71
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.46▼ 16.71%Market cap $1.69BP/E —$2.77$7.18
- MAZEMaze Therapeutics Inc. Common Stock$27.53▲ 0.18%Market cap $1.58BP/E —$21.95$53.65
- SLBTSL Science Holding Limited Ordinary Shares$1.53▼ 1.29%Market cap $1.53BP/E —$1.42$14.5
- TSHATaysha Gene Therapies Inc. Common Stock$3.62▼ 2.95%Market cap $1.82BP/E —$3.46$7.3
- VIRVir Biotechnology Inc. Common Stock$9.96▼ 4.87%Market cap $1.48BP/E —$4.82$12
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMCR Immunocore Holdings plc American Depositary Shares | $1.66B | — | $29.4 | ▼ 0.27% | $27.5$40.71 |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.46 | ▼ 16.71% | $2.77$7.18 |
| MAZE Maze Therapeutics Inc. Common Stock | $1.58B | — | $27.53 | ▲ 0.18% | $21.95$53.65 |
| SLBT SL Science Holding Limited Ordinary Shares | $1.53B | — | $1.53 | ▼ 1.29% | $1.42$14.5 |
| TSHA Taysha Gene Therapies Inc. Common Stock | $1.82B | — | $3.62 | ▼ 2.95% | $3.46$7.3 |
| VIR Vir Biotechnology Inc. Common Stock | $1.48B | — | $9.96 | ▼ 4.87% | $4.82$12 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Top 3 Healthcare Stocks To Watch In October 2026Yahoo · 10/10/2026
- Immunocore Hldgs Q2 2026 Earnings Call Transcriptbenzinga · 10/5/2026
- Immunocore Hldgs Q2 2026 Earnings Call TranscriptBenzinga · 10/5/2026
- Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel CrucialSeekingAlpha · 9/29/2026
- Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyYahoo · 9/15/2026
- Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaYahoo · 9/14/2026
- Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026Benzinga · 9/14/2026
Insider Activity
Insider Actions →- Bell John Irving · May 27, 2026 · Grant27.5K
- Kaul Siddharth · May 27, 2026 · Grant27.5K
- Herbst Roy Steven · May 27, 2026 · Grant27.5K
- Ratcliffe Peter John · May 27, 2026 · Grant27.5K
- Pao William · May 27, 2026 · Grant27.5K
- Peterson Kristine · May 27, 2026 · Grant27.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 54.19M
- Total value held
- $1.53B
- Institutional holders
- 142
- Unknown4.87M
- Unknown4.83M
- Unknown4.71M
- Unknown3.69M
- Unknown2.80M
- Unknown2.77M
- Unknown2.65M
- Unknown1.93M
- Unknown1.93M
- Unknown1.89M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Immunocore (IMCR) Listed in October Healthcare Watchlist
Immunocore Holdings was included in a Yahoo Finance list of top healthcare stocks to watch in October 2026. This inclusion highlights the company's relevance in the sector, although the stock currently trades near its 52-week low of $27.55. The share price sits close to a key support level at $28.58, while the average analyst target remains significantly higher at $62.73.
Immunocore (IMCR) Listed in October Healthcare Watchlist. Immunocore Holdings was included in a Yahoo Finance list of top healthcare stocks to watch in October 2026. This inclusion highlights the company's relevance in the sector, although the stock currently trades near its 52-week low of $27.55. The share price sits close to a key support level at $28.58, while the average analyst target remains significantly higher at $62.73.